Recent Studies Show How COVID-19 Vaccines Destroy Immune System

COVID-19 vaccinations cause depletion of important, virus-fighting IgG3 antibodies and replace them (class switch) with useless IgG4 antibodies. The IgG4 antibodies make the infection seem mild, but fail to clear the virus promptly. IgG4 antibodies have the opposite effect as all other types of antibodies & make our immune system ignore the particular antigen they are trained to detect. Basically, you took an allergy shot to train your body to accept COVID-19 instead of reject it.

IgG3 and IgG4 are subtypes of IgG antibodies, which are the most common type of antibody in the body. Both IgG3 and IgG4 are produced by long-lived plasma cells, which are a type of immune cell that produces antibodies.

IgG3 and IgG4 are structurally similar to each other and to other subtypes of IgG antibodies, but they have some differences in their biological properties.

One main difference between IgG3 and IgG4 is their affinity for certain types of antigens. Affinity refers to the strength of the interaction between an antibody and an antigen. IgG3 has a higher affinity for antigens compared to IgG4, which means that it is more strongly attracted to and binds more tightly to certain antigens. This difference in affinity can affect the ability of IgG3 and IgG4 to neutralize pathogens or stimulate an immune response.

Another difference between IgG3 and IgG4 is their role in the immune response. IgG3 is more effective at activating the complement system, which is a group of proteins that help to kill pathogens and stimulate an immune response. In contrast, IgG4 is less effective at activating the complement system and is more likely to inhibit the immune response.

IgG4 is less effective at binding to and neutralizing certain types of antigens compared to IgG3, which means that it may not be as effective at protecting against certain pathogens. In addition, IgG4 is less effective at activating the complement system, which is a key component of the immune response that helps to kill pathogens and stimulate an immune response. The inability of IgG4 to effectively activate the complement system may further reduce its effectiveness at protecting against certain pathogens.

Given the relative effectiveness of IgG3 compared to IgG4 at neutralizing pathogens and activating the immune response, a vaccine that encourages the production of IgG4 rather than IgG3 would likely be less effective at protecting against certain viruses and other pathogens. It’s also important to consider that the effectiveness of a vaccine is usually evaluated through clinical trials, which involve administering the vaccine to a large group of people and measuring the immune response it elicits and its ability to protect against the targeted pathogen. Skipping clinical trials can increase the risk of a vaccine or medical product, as it may not have been thoroughly tested in a controlled setting and may have unknown risks or side effects.

“Vaccines that induce an antibody response with a stronger skew toward IgG1 and IgG3 may offer better protection, potentially due to superior naturalization capacity. In contrast an immune environment with robust IgG2 and IgG4 response may contribute the disease progression.”
several months after the second vaccination, SARS-CoV-2-specific antibodies were increasingly composed of non-inflammatory IgG4, which were further boosted by a third mRNA vaccination and/or SARS-CoV-2 variant breakthrough infections. IgG4 antibodies among all spike-specific IgG antibodies rose on average from 0.04% shortly after the second vaccination to 19.27% late after the third vaccination. This induction of IgG4 antibodies was not observed after homologous or heterologous SARS-CoV-2 vaccination with adenoviral vectors. Single-cell sequencing and flow cytometry revealed substantial frequencies of IgG4-switched B cells within the spike-binding memory B-cell population (median 14.4%; interquartile range (IQR) 6.7–18.1%) compared to the overall memory B-cell repertoire (median 1.3%; IQR 0.9–2.2%) after three immunizations. Importantly, this class switch was associated with a reduced capacity of the spike-specific antibodies to mediate antibody-dependent cellular phagocytosis and complement deposition. Since Fc-mediated effector functions are critical for antiviral immunity, these findings may have consequences for the choice and timing of vaccination regimens using mRNA vaccines, including future booster immunizations against SARS-CoV-2.
all H4 subtypes were able to neutralize SARS-CoV-2. However, H4-IgG3 exhibited an up to 50-fold superior neutralization potency compared with the other subclasses. Our data point to a strong protective effect of IgG3 Abs in SARS-CoV-2 infection and suggest that superior neutralization might be a consequence of cross-linking the SP on the viral surface.

In summary, the mRNA vaccines encourage the production of IgG4 rather than IgG3, which are not effective at neutralizing pathogens or stimulating an immune response. The body ends up producing far more IgG4 than igG3, which is the opposite of what you would want from a vaccine. IgG3 is 50x better at neutralizing Covid-19. People are not training their immune systems to fight off Covid-19, instead they are training their body to accept disease progression.

I encourage you to view the articles by Rintrah, Jessica Rose, and Igor Chudov listed below as they understand this far more than I do and go into much more depth on the subject.